> ## Content Index
> Fetch the complete content index at: https://www.edgewisely.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Function Health's $450 Million Non-Dilutive Bet
- URL: https://www.edgewisely.com/function-healths-450-million-non-dilutive-bet/
- Published: 2026-09-01T11:47:03.000Z
- Updated: 2026-09-01T11:47:03.000Z
- Description: How General Catalyst is financing Function Health's growth without taking a single share of the company.
- Author: John Karpentar
- Tags: Healthcare, Startups

### How General Catalyst is financing Function Health's growth without taking a single share of the company.

**Function Health just raised $450 million without selling a piece of itself — the money comes back out of the customers it buys with it, not out of its cap table.**

On July 30, 2026, Function Health and General Catalyst announced $450 million in new growth financing — eight months after Function closed a $298 million Series B. Both rounds are big by health-tech standards. What makes the second one worth stopping on is the structure: no new shares, no new board seat, no dilution. General Catalyst's Customer Value Fund (CVF) is lending against the customers Function's marketing dollars are about to bring in, and it only gets repaid once those customers pay Function.

That is a different kind of bet than a typical venture round, and it says as much about where growth capital is headed as it does about Function Health itself.

## What happened

Function Health, the Austin-based membership platform that combines blood testing, imaging and an AI-driven health dashboard, said it secured $450 million in growth financing from General Catalyst's Customer Value Fund, according to [Fierce Healthcare](https://www.fiercehealthcare.com/health-tech/function-health-lands-450m-growth-financing-scale-tech-enabled-preventive-health?ref=edgewisely.com). The company plans to use the capital to bring its platform "to millions more people," per its announcement, rather than to fund a specific product launch.

The round lands eight months after Function's $298 million Series B, a round led by Redpoint Ventures that valued the company at $2.5 billion and closed in November 2025, as [Fierce Healthcare reported](https://www.fiercehealthcare.com/health-tech/function-health-lands-298m-series-b-rolls-out-medical-intelligence-ai-model-health-data?ref=edgewisely.com) at the time. Add Function's earlier $53 million Series A, and the company has now raised more than $800 million since launching in 2023 — a pace of fundraising that puts it in the same league as this year's [other supersized growth rounds](https://www.edgewisely.com/fireworks-ai-series-d-17-5-billion-valuation/), even outside of AI infrastructure.

The financing follows two acquisitions Function made in the second quarter of 2026: Getlabs, which operates a nationwide network for at-home and in-office blood draws, and SuppCo, a supplement-tracking platform, according to [HIT Consultant](https://hitconsultant.net/2026/08/03/function-health-secures-450m-growth-financing-general-catalyst/?ref=edgewisely.com). Those deals came a year after Function's May 2025 acquisition of Ezra, the AI-powered full-body imaging company that gave Function its MRI and CT business. Together, the three acquisitions turn Function from a lab-testing subscription into something closer to a vertically integrated health-data company: it now owns the blood draw, the imaging referral network, the supplement recommendation and the software that ties the results together.

Function's core product has not changed shape. Membership starts at $365 a year and includes access to more than 160 lab tests, run twice annually, covering heart, hormone, thyroid, liver and kidney markers along with nutrient levels, inflammation, heavy-metal exposure and cancer signals, according to [MobiHealthNews](https://www.mobihealthnews.com/news/function-health-secures-450m-growth-financing?ref=edgewisely.com). Members can add MRI and CT imaging for under $1,000 through a network of more than 200 partner locations. Results, imaging and now supplement data flow into an app built on what Function calls its Medical Intelligence Lab, which is meant to flag changes in a person's biomarkers over time rather than deliver a single point-in-time result.

Co-founder and CEO Jonathan Swerdlin framed the raise in mission terms rather than product terms: "Our mission is simple: enable you to live 100 healthy years," he said in the announcement, adding, "Everyone deserves to feel their best and avoid suffering," as [Fierce Healthcare quoted him](https://www.fiercehealthcare.com/health-tech/function-health-lands-450m-growth-financing-scale-tech-enabled-preventive-health?ref=edgewisely.com). Pranav Singhvi, partner and co-head of General Catalyst's Customer Value Fund, was more explicit about the thesis behind the check, calling Function "one of the defining companies of our generation."

## How the Customer Value Fund actually works

The mechanics matter here more than the number, because "$450 million" tells you almost nothing about what General Catalyst actually bought.

General Catalyst's Customer Value Fund is built to finance a company's sales and marketing spending specifically — not its balance sheet, not a factory, not a cap table event. In exchange, the fund takes a capped share of the value generated by the customers who were acquired using that capital, and it is paid only when the company itself is paid, according to [MobiHealthNews](https://www.mobihealthnews.com/news/function-health-secures-450m-growth-financing?ref=edgewisely.com). If Function spends CVF's money to sign up a new member, a portion of that member's revenue flows back to General Catalyst over time, up to a cap; if that member never converts or churns immediately, the fund doesn't collect on them. No equity changes hands and no share price gets set in the process.

That structure solves a specific problem for a company like Function. A subscription business with a known cost to acquire a customer and a predictable, recurring revenue stream per customer is, in principle, a good candidate for debt-like financing — the future cash flows are more forecastable than a typical venture bet on an unproven product. But traditional venture debt still prices in downside risk across the whole company, and traditional equity dilutes founders and existing shareholders every time it is raised. The Customer Value Fund is General Catalyst's attempt to split the difference: underwrite the marketing spend against the specific revenue it generates, and leave the company's ownership table untouched.

It also changes the incentive structure. A venture investor is rewarded by the company's valuation going up regardless of how any single customer cohort performs. A Customer Value Fund check is repaid, or not, based on whether the customers acquired with that specific tranche of capital actually generate revenue. That is a bet on unit economics working at scale, not a bet on a narrative holding up long enough to raise the next round. For a company that has already raised a $298 million Series B eight months earlier, layering on a repayment-tied structure rather than another priced round is also a signal: Function evidently didn't need to mark up its valuation again, or didn't want to, and General Catalyst was comfortable enough in the durability of Function's customer economics to underwrite growth spend directly.

## Who this actually affects

**For Function Health**, the deal buys scale without diluting the ownership that already survived a $2.5 billion Series B. It also buys time to prove out the Getlabs and SuppCo acquisitions before the next priced round has to justify a higher number. Integrating a nationwide phlebotomy network and a supplement platform into a single consumer app is an operational lift, not a financing problem, and $450 million earmarked for customer acquisition gives Function room to grow the top of the funnel while that integration work happens in the background.

**For General Catalyst**, the Customer Value Fund is itself the story. The firm has spent the past several years building alternative-capital vehicles for growth-stage companies with predictable revenue, and Function is now one of its highest-profile bets on the model. If Function's customer cohorts perform as underwritten, CVF gets repaid on a set of health-tech customer relationships without ever owning a share of the business — a return profile closer to structured credit than venture capital. If the bet is wrong and acquired customers churn faster than modeled, the fund absorbs that risk without a board seat or governance rights to fall back on.

**For competitors** in consumer preventive health — Prenuvo, Ezra's former independent business, and the broader field of direct-to-consumer testing and imaging startups, alongside the wider [healthcare AI vendor landscape](https://www.edgewisely.com/top-7-healthcare-ai-companies-2026/) chasing clinical and consumer budgets alike — Function's ability to raise $450 million in non-dilutive capital on top of a $298 million equity round eight months earlier raises the cost of competing on customer acquisition. A rival funding a comparable ad spend entirely with equity is diluting itself to match a competitor that isn't.

**For members and prospective members**, the financing is largely invisible in the product itself: Function's test menu, pricing and imaging network don't change because of how the marketing budget behind them was financed. What does change is the pace at which Function can advertise, and the degree to which its unit economics — how much a new member actually costs to acquire and how much they're worth over time — are now being independently underwritten by an outside financial firm, which is itself a kind of external validation of the subscription math.

## The skepticism this doesn't erase

None of this financing structure answers the clinical question that has followed Function, Ezra and comparable whole-body screening companies since before this deal: does routinely testing asymptomatic people for dozens of biomarkers and scanning their entire bodies actually improve health outcomes, or does it mostly generate anxiety and follow-up procedures that were never medically necessary?

The American College of Radiology has said it does not support whole-body MRI as a screening tool for people without symptoms, and the debate among radiologists over that stance has been public and pointed. In a set of dueling opinion pieces covered by [Radiology Business](https://radiologybusiness.com/topics/healthcare-management/medical-practice-management/physicians-debate-perils-and-promise-whole-body-mri-screening?ref=edgewisely.com), Penn Medicine radiologist Saurabh Jha argued that whole-body MRI screening risks converting healthy people into anxious patients chasing incidental findings with no proven benefit, warning that the technology's commercial success has outrun the evidence for it. NYU's Daniel Sodickson, who has advised Ezra, took the opposing position — that dismissing imaging-based screening outright ignores a broader shift toward proactive, personalized care — while still acknowledging the field lacks clinical trials showing regular whole-body monitoring improves outcomes in a healthy population.

That disagreement hasn't gone away just because Function folded Ezra's imaging business into a larger, better-funded platform. If anything, a $450 million growth round aimed at reaching "millions more people" raises the stakes on the underlying question, because it means more asymptomatic people being tested and scanned at a rate the evidence base hasn't caught up to. Function's own numbers on how many members get a clinically meaningful early catch versus how many get an incidental finding that leads nowhere have not been independently published. That gap is worth watching as the company scales — it's the same evidence-versus-adoption tension that shows up on the clinical side, where [hospital AI pilots](https://www.edgewisely.com/the-95-problem-why-hospital-ai-pilots-still-dont-pay-off/) routinely outrun the proof that they improve outcomes.

## Takeaways

Function Health's $450 million round is less a story about a hot consumer-health brand raising more money than about how growth capital itself is evolving. The Customer Value Fund structure lets General Catalyst underwrite a specific, measurable slice of Function's business — new customer acquisition — without touching the rest of the company, and it lets Function keep growing without repricing itself or handing out more of the company it already priced at $2.5 billion eight months ago. It is a financing innovation dressed up as a funding headline.

The acquisitions behind the raise matter just as much as the raise itself. By owning Getlabs' blood-draw network and SuppCo's supplement platform on top of Ezra's imaging capability, Function has quietly assembled the full stack of a preventive-health business — collection, testing, imaging, recommendation and software — rather than remaining a lab-results app that partners with everyone else's infrastructure. That vertical integration is what makes a non-dilutive, revenue-linked financing structure plausible in the first place: the more of the customer relationship a company owns end to end, the more predictable its unit economics look to a lender.

And the clinical skepticism hasn't resolved, it's just been outpaced by the capital. Whether more testing and more scanning of healthy people produces better health outcomes or mostly better funnels remains an open, contested question inside radiology and preventive medicine. Function's investors are betting the business model works regardless of how that debate settles.

## Zoom-out

The interesting thing about a Customer Value Fund isn't that it's non-dilutive — plenty of debt is non-dilutive. It's that it ties an outside investor's return directly to whether a specific customer, acquired with a specific dollar, actually generates revenue. That is a more honest instrument than a priced equity round, which rewards a rising valuation whether or not the underlying customers ever pay their way. Growth capital built like that doesn't just fund Function Health's next chapter — it puts a price on the one thing every subscription business claims to know but rarely has to prove: what a customer is actually worth.

## Frequently Asked Questions

**What is General Catalyst's Customer Value Fund?** It's a financing vehicle that funds a company's sales and marketing spending. In return, the fund receives a capped share of the revenue generated by customers acquired with that capital, paid only when the company gets paid. No equity or board seats change hands.

**How much has Function Health raised in total?** Function has raised more than $800 million since launching in 2023: a $53 million Series A, a $298 million Series B in November 2025 at a $2.5 billion valuation, and the new $450 million Customer Value Fund financing announced in July 2026.

**What do Getlabs and SuppCo add to Function Health?** Getlabs gives Function a nationwide network for at-home and office blood draws, replacing reliance on third-party labs. SuppCo adds a supplement-tracking platform, letting Function turn biomarker results directly into product recommendations inside its own app.

**Is whole-body screening backed by strong clinical evidence?** Not conclusively. The American College of Radiology does not endorse whole-body MRI for screening people without symptoms, and radiologists remain split over whether routine screening of healthy people improves outcomes or mainly generates incidental findings and unnecessary follow-up care.

*Editor's note — additional sources consulted:* [*MedCity News*](https://medcitynews.com/2026/07/general-catalyst-function-health-funding/?ref=edgewisely.com)*,* [*Modern Healthcare*](https://www.modernhealthcare.com/providers/mh-function-health-general-catalyst/?ref=edgewisely.com)*,* [*DOTmed News*](https://www.dotmed.com/news/story/66672?ref=edgewisely.com)*.*

*Illustration: Edgewisely*